乙醯左旋肉鹼 Acetyl-L-Carnitine × 神經病變

結論:證據分歧

The evidence does not support a single grade because it splits sharply by neuropathy type.

C 🟠 C 薄弱證據 證據分歧 low — community discussion mostly non-commercial
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

The evidence does not support a single grade because it splits sharply by neuropathy type. For DIABETIC peripheral neuropathy (DPN), several RCTs and a 2015 meta-analysis (PMID 25751285, n=523) show a modest, dose-dependent pain reduction with the diabetic subgroup outperforming non-diabetic patients, but the most rigorous synthesis, the 2019 Cochrane review (PMID 31201734, n=907), rated certainty of evidence as VERY LOW and the two largest positive trials were industry-sponsored (Sigma-Tau), so the DPN signal is at best weakly positive and uncertain. For CHEMOTHERAPY-induced peripheral neuropathy (CIPN) the evidence is the opposite direction: a high-quality phase-III SWOG/CALGB RCT (PMID 23733756, n=409) found ALCAR significantly WORSENED neuropathy (FACT-NTX 1.8 points worse, p=0.01), and ASCO explicitly recommends against its use for both prevention and treatment of CIPN. Averaging a weakly-positive-but-uncertain DPN signal against a documented-harm CIPN signal yields an honest overall grade of C, with the firm condition that the two indications must never be conflated. Examine independently graded the diabetic-neuropathy outcome C, which aligns with this assessment for the DPN slice only.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.45
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 證據分歧
信心度
75%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧/統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L5 臨床機構權威立場
0.40
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Acetyl-L-Carnitine in the Treatment of Peripheral Neuropathic Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 25751285 2015 統合分析 n = 523
結論:Across 4 RCTs (n=523), ALC significantly reduced VAS pain scores versus placebo (MD 1.20, 95% CI 0.68 to 1.72, p<0.00001). The effect was larger in diabetic neuropathy patients (MD 1.47, 95% CI 1.06 to 1.87, p<0.00001) than in non-diabetic patients (MD 0.71, 95% CI -0.01 to 1.43, p=0.05). No severe adverse events related to ALC were reported.
效應量:MD VAS 1.20 (all); 1.47 (diabetic subgroup); 0.71 NS (non-diabetic subgroup)
前往 PubMed
Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy (Cochrane Systematic Review)
PMID: 31201734 2019 Cochrane SR n = 907
結論:Across 4 RCTs (n=907), ALC showed a modest pain reduction versus placebo at 6-12 months (MD -9.16 on a 0-100 VAS, 95% CI -16.76 to -1.57), with benefit apparently confined to doses above 1500 mg/day. The Cochrane authors rated the certainty of evidence as VERY LOW and concluded they are very uncertain whether ALC reduces pain in DPN; evidence is sparse and effects on function and quality of life are uncertain.
🟠 品質有限 效應量:MD VAS -9.16/100 (very low certainty)
前往 PubMed
Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An Analysis of Two Randomized Placebo-Controlled Trials
PMID: 15616239 2005 隨機對照試驗 n = 1,257
結論:Pooled analysis of two large industry-sponsored RCTs (n=1257) found the 1000 mg three-times-daily dose significantly reduced pain and improved nerve fiber regeneration and vibratory perception versus placebo in chronic diabetic neuropathy; benefit was greater in patients treated earlier in the disease course.
⚠️ 廠商資助 效應量:Significant pain reduction and improved nerve regeneration at 3000 mg/day
前往 PubMed
Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomized, double-blind, controlled trial
PMID: 27180954 2016 隨機對照試驗 n = 232
結論:In 232 patients with DPN, ALC 500 mg three times daily was non-inferior to methylcobalamin in improving neuropathic symptoms and neurophysiological parameters over 24 weeks, and was well tolerated. This is a non-inferiority design without a placebo arm, so it cannot establish absolute efficacy.
效應量:Non-inferior to methylcobalamin (no placebo comparison)
前往 PubMed
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy
PMID: 23733756 2013 隨機對照試驗 n = 409
結論:COUNTER-EVIDENCE / HARM SIGNAL: In 409 breast cancer patients (208 ALC, 201 placebo), ALC did not prevent and in fact WORSENED chemotherapy-induced peripheral neuropathy. At 24 weeks FACT-NTX scores were 1.8 points lower (worse) with ALC (95% CI -3.2 to -0.4, p=0.01), and significantly more ALC patients had clinically meaningful neuropathy worsening (38% vs 28%, p=0.05). The harm persisted over long-term follow-up.
🟢 高品質 政府資助 效應量:FACT-NTX 1.8 points WORSE with ALC at 24 weeks (p=0.01) - harm
前往 PubMed

L4a US FDA
謹慎
NUTRIENT SUPPLEMENT [21 CFR 170.3(o) technical effect — substance: Carnitine / L-carnitine / Levocarnitine, CAS 541-15-1] 來源↗
L4b EU EFSA
反對
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
形態屬膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,L-肉鹼(L-carnitine)總含量不得高於 2 公克。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
謹慎
In a few studies, people with diabetic neuropathy who took acetyl-L-carnitine supplements had less pain and improvements in their ability to perceive vibrations, as well as improvements in nerve function tests. Some of these studies suggest that acetyl-L-carnitine eases pain better when people start taking it soon after diabetic neuropathy begins. 來源↗
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
謹慎

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 低度
📍立場總覽

台灣社群幾乎沒有乙醯左旋肉鹼專門用於「神經病變」的鄉民實測。PTT 對 ALCAR 的討論集中在健身板(MuscleBeach)的減脂/抗疲勞與少量補腦/抗老情境,評價偏保守(『我有吃,沒什麼感覺』『輔助效果因人而異』)。「ALCAR 改善糖尿病/周邊神經痛」的中文敘述幾乎全來自保健品 SEO 文、藥師衛教與部落格(痞客邦/vocus/formulawave),而非匿名社群實測辯證;神經病變適應症並非台灣社群討論主題,屬冷門題目。

💬社群實感

無共識(台灣 PTT/Dcard/Mobile01 幾乎無 ALCAR 用於神經病變的在地實測;既有討論集中於減脂/抗疲勞/補腦情境且評價保守,神經病變/糖尿病神經痛的中文內容多為保健品 SEO 與藥師衛教文,非匿名社群真實回饋)

破解迷思 社群最常見的 2 個誤解
事實把「乙醯左旋肉鹼(ALCAR)」與一般減脂用「左旋肉鹼(L-carnitine)」混為一談(社群有人明確指出兩者不同),誤以為吃減脂左旋肉鹼即可顧神經
事實誤把保健品當神經病變特效藥,以為服用 ALCAR 可取代糖尿病血糖控制與正規神經病變治療(此宣稱多源自 SEO/部落格而非社群實證)

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

NOW Foods, Acetyl-L-Carnitine, 500 mg, 100 Veg Capsules

代表來源 ↗
L10b · TFDA 法定身份 官方認定

形態屬膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,左旋肉鹼總含量不得高於2公克

來源 ↗

  • 血糖控制(強化血糖管理)
  • 神經痛藥物(gabapentinoids 與 SNRI)
  • 三環抗憂鬱劑(如 amitriptyline)
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v24 engine_version: v1.0 claim_id: CLM-COND-neuropathy-INT-acetyl-l-carnitine-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-neuropathy-INT-acetyl-l-carnitine-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "乙醯左旋肉鹼能改善神經病變",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}